MoonLake Immunotherapeutics
MLTX10.630USD
+0.340+3.30%
收盤 11/07, 16:00（美東）報價延遲15分鐘
677.18M總市值
虧損本益比TTM
關於 MoonLake Immunotherapeutics 公司
MoonLake Immunotherapeutics 前身爲 Helix Acquisition Corp，是一家從事醫療保健行業的瑞士公司。該公司是一家臨牀階段的生物製藥公司，專注於開發治療免疫疾病的藥物，包括炎症性皮膚病和關節病。該公司開發了三特異性納米抗體 Sonelokimab (SLK)，其目的是靶向和穿透難以到達的發炎組織。SLK 是一種在深層皮膚和關節中富集度增強且靶標結合力強的分子。SLK 通過獨立抑制引起患者炎症的天然 IL-17 A/A、A/F 和 F/F 二聚體來抑制 IL-17A 和 IL-17F 抑制以治療炎症性疾病。
MoonLake Immunotherapeutics簡介
公司代碼MLTX
公司名稱MoonLake Immunotherapeutics
上市日期Oct 20, 2020
CEODr. Jorge Santos Da Silva
員工數量100
證券類型Ordinary Share
年結日Oct 20
公司地址Dorfstrasse 29
城市ZUG
上市交易所NASDAQ Capital Market Consolidated
國家Switzerland
郵編6300
電話41415108022
網址https://moonlaketx.com/
公司代碼MLTX
上市日期Oct 20, 2020
CEODr. Jorge Santos Da Silva
MoonLake Immunotherapeutics公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.13M
+1.59%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
3.08M
--
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
627.54K
+1.76%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.13M
+1.59%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
3.08M
--
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
627.54K
+1.76%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 11月4日 週二
更新時間: 11月4日 週二
持股股東
股東類型
持股股東
持股股東
佔比
BVF Partners L.P.
27.67%
Fidelity Management & Research Company LLC
7.44%
Avoro Capital Advisors LLC
5.81%
Reich (Kristian)
4.38%
Santos da Silva (Jorge)
4.31%
其他
50.37%
持股股東
持股股東
佔比
BVF Partners L.P.
27.67%
Fidelity Management & Research Company LLC
7.44%
Avoro Capital Advisors LLC
5.81%
Reich (Kristian)
4.38%
Santos da Silva (Jorge)
4.31%
其他
50.37%
股東類型
持股股東
佔比
Hedge Fund
41.51%
Investment Advisor
20.11%
Investment Advisor/Hedge Fund
17.19%
Individual Investor
11.03%
Research Firm
2.11%
Venture Capital
1.30%
Bank and Trust
0.07%
Pension Fund
0.05%
其他
6.62%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
336
52.26M
73.22%
-13.87M
2025Q2
326
71.15M
112.06%
-8.45M
2025Q1
329
71.47M
112.59%
-8.98M
2024Q4
308
74.57M
117.86%
+1.09M
2024Q3
292
73.42M
116.42%
+551.38K
2024Q2
282
72.21M
114.78%
+1.82M
2024Q1
274
70.82M
112.58%
-306.27K
2023Q4
260
64.82M
107.09%
-2.17M
2023Q3
219
60.33M
114.64%
-5.55M
2023Q2
175
60.28M
100.54%
+9.44M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BVF Partners L.P.
19.75M
31.1%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
5.31M
8.36%
-114.00K
-2.10%
Jun 30, 2025
Avoro Capital Advisors LLC
4.15M
6.54%
+1.38M
+49.81%
Jun 30, 2025
Reich (Kristian)
3.13M
4.93%
+48.98K
+1.59%
Sep 02, 2025
Santos da Silva (Jorge)
3.08M
4.85%
--
--
Mar 15, 2025
T. Rowe Price Associates, Inc.
2.61M
4.12%
-360.60K
-12.13%
Jun 30, 2025
Cormorant Asset Management, LP
1.99M
3.14%
-6.50M
-76.52%
Sep 30, 2025
Citadel Advisors LLC
1.67M
2.64%
+195.41K
+13.22%
Jun 30, 2025
Westfield Capital Management Company, L.P.
1.26M
1.98%
-175.39K
-12.22%
Jun 30, 2025
Goldman Sachs & Company, Inc.
1.26M
1.98%
-19.32K
-1.52%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
ALPS Medical Breakthroughs ETF
0.27%
Global X Guru Index ETF
0.16%
Goldman Sachs Future Health Care Equity ETF
0.12%
Virtus LifeSci Biotech Clinical Trials ETF
0.12%
JPMorgan Healthcare Leaders ETF
0.03%
First Trust IPOX Europe Equity Opportunities ETF
0.02%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.01%
John Hancock Multifactor Small Cap ETF
0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
0.01%
Fidelity Blue Chip Growth ETF
0.01%
查看更多
ALPS Medical Breakthroughs ETF
佔比0.27%
Global X Guru Index ETF
佔比0.16%
Goldman Sachs Future Health Care Equity ETF
佔比0.12%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.12%
JPMorgan Healthcare Leaders ETF
佔比0.03%
First Trust IPOX Europe Equity Opportunities ETF
佔比0.02%
JPMorgan BetaBuilders US Small Cap Equity ETF
佔比0.01%
John Hancock Multifactor Small Cap ETF
佔比0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
佔比0.01%
Fidelity Blue Chip Growth ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
